Details of the Drug
General Information of Drug (ID: DM2P7YX)
Drug Name |
1-(2-Ethoxy-phenyl)-piperazine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-(2-Ethoxyphenyl)piperazine; 13339-01-0; 1-(2-Ethoxy-phenyl)-piperazine; CHEMBL273923; Piperazine,1-(2-ethoxyphenyl)-; FBQIUSDQWOLCNY-UHFFFAOYSA-N; 1-(2-Ethoxyphenyl)piperazinium chloride; ehoxyphenylpiperazine; EINECS 236-389-0; AC1Q57PR; AC1Q37ZC; Oprea1_356570; labotest-bb lt00233165; 4(2-eth-oxyphenyl)piperazine; SCHEMBL255189; 2-ethoxy-1-piperazinylbenzene; 1-(2-ehoxyphenyl)-piperazine; N-(2-ethoxyphenyl)-piperazine; AC1L359U; 1-(2-ethoxyphenyl)-piperazine; N-(2-ethyoxyphenyl)-piperazine; CTK4B8518
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 206.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||